Antithrombin III inhib 
Welcome,         Profile    Billing    Logout  
 0 Companies  0 Products   0 Products   0 Diseases   0 Trials   1 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fitusiran (SAR439774) / Sanofi
ATLAS-PEDS, NCT03974113 / 2019-000679-18: Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Calendar Jan 2024 - Dec 2024: Data from ATLAS-PEDS trial for hemophilia A and B
Active, not recruiting
3
32
Europe, Canada, US, RoW
Fitusiran, SAR439774
Genzyme, a Sanofi Company
Hemophilia
02/28
08/28
ATLAS-NEO, NCT05662319: A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Active, not recruiting
3
79
Europe, Canada, Japan, US, RoW
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Sanofi
Hemophilia
09/26
06/28
ATLAS-OLE, NCT03754790 / 2018-002880-25: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Calendar Jan 2025 - Dec 2025: From ATLAS-PEDS trial for hemophilia A and B
Active, not recruiting
3
281
Europe, Canada, Japan, US, RoW
Fitusiran
Genzyme, a Sanofi Company
Hemophilia
11/26
11/26
NCT02554773 / 2015-001395-21: An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Calendar Jan 2024 - Dec 2024: Data from trial for hemophilia A and B
Checkmark Additional data from OLE study at ISTH 2017
Jul 2017 - Jul 2017: Additional data from OLE study at ISTH 2017
Checkmark Presentation from open label extension trial for hemophilia A or B without inhibitors at ASH 2016
Dec 2016 - Dec 2016: Presentation from open label extension trial for hemophilia A or B without inhibitors at ASH 2016
Completed
1/2
34
Europe, US, RoW
Fitusiran (SAR439774)
Genzyme, a Sanofi Company
Hemophilia A, Hemophilia B
03/23
03/23
NCT06145373: A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Recruiting
1
20
RoW
Fitusiran (SAR439774), SAR439774, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Sanofi
Hemophilia A
09/26
05/28
PRO-03 / Prothix
No trials found

Download Options